Jacob R. Haling, Ph.D.
Affiliations: | 2010 | Molecular Pathology | University of California, San Diego, La Jolla, CA |
Area:
Cell Biology, Molecular Biology, BiochemistryGoogle:
"Jacob Haling"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Mark H. Ginsberg | grad student | 2010 | UCSD | |
| (The dynamic interplay between adhesion signaling and the ERK MAP kinase pathway.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hallin J, Bowcut V, Calinisan A, et al. (2022) Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor. Nature Medicine |
| Ramurthy S, Taft BR, Aversa RJ, et al. (2019) Design and Discovery of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (LXH254)- A selective, efficacious and well-tolerated RAF inhibitor targeting RAS mutant cancers: The path to the clinic. Journal of Medicinal Chemistry |
| Shao W, Mishina Y, Feng Y, et al. (2018) Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF. Cancer Research |
| Stuart DD, Shao W, Mishina Y, et al. (2018) Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor Cancer Research. 78 |
| Emery CM, Monaco KA, Wang P, et al. (2017) BRAF-inhibitor associated MEK Mutations Increase RAF-dependent and-independent Enzymatic Activity. Molecular Cancer Research : McR |
| Nishiguchi GA, Rico A, Tanner HR, et al. (2017) Design and Discovery of N-(2-methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A potent, selective and efficacious RAF inhibitor targeting RAS mutant cancers. Journal of Medicinal Chemistry |
| Haling JR, Sudhamsu J, Yen I, et al. (2014) Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell. 26: 402-13 |
| Hatzivassiliou G, Haling JR, Chen H, et al. (2013) Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 501: 232-6 |
| Haling JR, Sudhamsu J, Hatzivassiliou G, et al. (2013) Abstract LB-60: The BRAF:MEK complex reveals new therapeutic strategies for targeting KRASMTtumors. Cancer Research. 73 |
| Shiva M, Haling JR, Sudhamsu J, et al. (2013) Abstract 2346: A B-RAF-MEK complex reveals a kinase-independent role for BRAF in MAPK pathway suppression. Cancer Research. 73: 2346-2346 |